Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study
W. B. Kannel, T. Gordon, W. P. Castelli, J. R. Margolis

Perhaps the most remarkable and certainly one of the best known epidemiological studies in the history of medicine is the Framingham Heart Study. For 50 years, the residents of Framingham, Massachusetts, USA, have been synonymous with the remarkable advances made in the prevention of heart disease....

Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method
R. B. Devereux, N. Reichek

For many years, electrocardiography was used as the standard noninvasive method for detecting the presence of left ventricular hypertrophy (LVH); LVH detection assumed widespread importance with the realization that it provided an accurate and independent predictor of coronary heart disease and cardiac death...

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
D. Levy, R. J. Garrison, D. D. Savage, W. B. Kannel, W. P. Castelli

This paper follows on very naturally from the two discussed above. To recap, the first by Kannel et al (the same group as that who conducted the present study) demonstrated that left ventricular hypertrophy (LVH) on the electrocardiogram predicted future risk of coronary heart disease...

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group.
G. Mancia, A. Zanchetti, E. Agabiti-Rosei, G. Benemio, R. De Cesaris, R. Fogari, A. Pessina, C. Porcellati, A. Rappelli, A. Salvetti, et al

Determination of office blood pressure (OBP) has, for many decades, been the standard method for detecting hypertension and its response to treatment...

Signaling pathways for cardiac hypertrophy and failure
J. J. Hunter, K. R. Chien

Hunter and Chien, in this paper, provide a very good overview of the cellular and molecular changes associated with cardiac hypertrophy and failure...

Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment
M. L. Muiesan, M. Salvetti, D. Rizzoni, M. Castellano, F. Donato, E. Agabiti-Rosei

Muiesan et al, in this study, return to the theme of whether left ventricular hypertrophy (LVH) is an important and independent predictor of cardiovascular events...

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
B. Dahlöf, R. B. Devereux, S. E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, et al; LIFE Study Group

Reporting on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the authors address the age-old question of whether any particular type of antihypertensive drug offers advantages over others...

Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy
G. Shimizu, Y. Hirota, Y. Kita, K. Kawamura, T. Saito, W. H. Gaasch

For many years, it was unclear whether myocardium that had undergone pressure-overload hypertrophy, for example, in response to hypertension, exhibited normal contractility during systole...

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
J. Mathew, P. Sleight, E. Lonn, D. Johnstone, J. Pogue, Q. Yi, J. Bosch, B. Sussex, J. Probstfield, S. Yusuf; Heart Outcomes Prevention Evaluation (HOPE) Investigators

This paper addresses the question of whether regression of left ventricular hypertrophy (LVH) gives rise to an improvement in cardiovascular morbidity and mortality, irrespective of effects on blood pressure...

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension
A. U. Klingbeil, M. Schneider, P. Martus, F. H. Messerli, R. E. Schmieder

As mentioned in the preceding summary, one of the major questions that has plagued physicians involved in the treatment of hypertension over the last 40 years, with the development of various classes of antihypertensive drug with different mechanisms of action, is whether any drug class is superior to any other in terms of preventing cardiovascular morbidity and mortality...